Dr. Aggarwal on study of androgen annihilation in biochemically relapsed prostate cancer

Rahul Aggarwal, MD, discusses the phase 3 PRESTO trial, which he presented at the 2022 ESMO Congress.

The study found that intensification of androgen-deprivation therapy (ADT) with the addition of the androgen receptor inhibitor apalutamide (Erleada) improved outcomes versus ADT alone in patients with high-risk biochemically relapsed prostate cancer.

The findings also showed, however, that while a third study arm of apalutamide/ADT plus acetate (Zytiga) and prednisone improved outcomes versus ADT alone, there was not a significant additional benefit with this regimen compared with the other experimental arm of just apalutamide/ADT.

Aggarwal is associate professor of Hematology/Oncology, University of California, San Francisco (UCSF), and associate director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center.